Skip to content
value.today

Hinge Bio, Inc.

🇺🇸 Burlingame, California, USABiotechnologyFounded 2015
Total raised
$49 M
2 rounds on record
Latest round
$31 M
Dec 2024
First round on record
Feb 2020
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Hinge Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$31 MNo. 2$10 to $50 million

Hinge Bio, Inc.: Raise no. 2, Dec 2024

Investors in this round

82 investors had bought by the notice of Jan 15, 2025: 82 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$31 M of $41 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harold E. Selick, PhD · Executive Officer, Director
  • Miriam Misha Siekevitz · Executive Officer
  • Alex E. Silverstein · Director
  • Jeffrey Misha Long-McGie · Director
  • John Misha Petkevich · Director
  • Malcolm E. Gefter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Portions of the amount under Total Remaining to be Sold is committed to be purchased in a subsequent closing contingent upon milestone achievement.”

Signed by Harold E. Selick, PhD, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 15, 2025. Read the notice at the SEC.

equitySEC
Feb 2020$18 MNo. 1$10 to $50 million

Hinge Bio, Inc.: Raise no. 1, Feb 2020

Investors in this round

100 investors had bought by the notice of Apr 28, 2020: 100 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $19 M offered; $1 M still to sell
Smallest investment taken
$1
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$833,776
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carin M. Rollins · Executive Officer, Director
  • Miriam D. Siekevitz · Executive Officer
  • Daniel J. Capon · Director
  • J. Misha Petkevich · Director
  • Malcolm L. Gefter · Director
  • Samuel Misha Saks · Director
  • William D. Unger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Arcadia Securities, LLC (CRD 44656) · New York, New YorkSold in AK, AZ, CA, CO, CT, DE, FL, IL, MD, MI, MS, NC, NJ, NY, OH, PA, TX, WY

Signed by Carin M. Rollins, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Apr 28, 2020. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hinge Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2025

That is all the official record says: Hinge Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Hinge Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 100 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hinge Bio, Inc.
NameRoleNamed in
Harold E. Selick, PhDExecutive officerJan 2025
Miriam Misha SiekevitzExecutive officerJan 2025
Carin M. RollinsExecutive officerApr 2020
Miriam D. SiekevitzExecutive officerApr 2020
Alex E. SilversteinDirectorJan 2025
Harold E. Selick, PhDDirectorJan 2025
Jeffrey Misha Long-McGieDirectorJan 2025
John Misha PetkevichDirectorJan 2025
Malcolm E. GefterDirectorJan 2025
Carin M. RollinsDirectorApr 2020
Daniel J. CaponDirectorApr 2020
J. Misha PetkevichDirectorApr 2020
Malcolm L. GefterDirectorApr 2020
Samuel Misha SaksDirectorApr 2020
William D. UngerDirectorApr 2020